Literature DB >> 20885432

Is it safer CARs that we need, or safer rules of the road?

Richard P Junghans.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20885432      PMCID： PMC2951568          DOI： 10.1038/mt.2010.162

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  9 in total

Review 1.  Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies.

Authors:  Megan Sykes; Thomas R Spitzer
Journal:  Cancer Treat Res       Date:  2002

2.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

3.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

4.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors:  Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

6.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies.

Authors:  Richard Paul Junghans
Journal:  J Transl Med       Date:  2010-06-10       Impact factor: 5.531

Review 8.  The T-body approach: redirecting T cells with antibody specificity.

Authors:  Z Eshhar
Journal:  Handb Exp Pharmacol       Date:  2008

9.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

Authors:  S Mackinnon; E B Papadopoulos; M H Carabasi; L Reich; N H Collins; F Boulad; H Castro-Malaspina; B H Childs; A P Gillio; N A Kernan
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113
  9 in total
  5 in total

1.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

2.  Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

Authors:  Partow Kebriaei; Helen Huls; Bipulendu Jena; Mark Munsell; Rineka Jackson; Dean A Lee; Perry B Hackett; Gabriela Rondon; Elizabeth Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2012-01-17       Impact factor: 5.695

3.  Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.

Authors:  Seogkyoung Kong; Sadhak Sengupta; Betty Tyler; Anthony J Bais; Qiangzhong Ma; Saryn Doucette; Jinyuan Zhou; Ayguen Sahin; Bob S Carter; Henry Brem; Richard P Junghans; Prakash Sampath
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

Review 4.  Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Authors:  Zhenguang Wang; Yelei Guo; Weidong Han
Journal:  Protein Cell       Date:  2017-05-02       Impact factor: 14.870

Review 5.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.